Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG CLASS:
Natural cytotoxicity triggering receptor 1 agonist
DRUG CLASS:
Natural cytotoxicity triggering receptor 1 agonist
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related drugs:
‹
SAR443579 (1)
NY-303 (0)
NY-338 (0)
SAR443579 (1)
NY-303 (0)
NY-338 (0)
›
Associations
(1)
News
Trials
Phase
Status
Apply
Phase
Status
Apply
First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) (TCD17197) (NCT05086315)
Phase 1/2
Sanofi
Sanofi
Recruiting
Phase 1/2
Sanofi
Recruiting
Last update posted :
05/29/2024
Initiation :
12/08/2021
Primary completion :
12/11/2025
Completion :
11/11/2026
IL3RA
|
SAR443579
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login